Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1237-1247

  Kennedy, Alan ^a   Hennessy, Martina ^a   Bergin, Colm ^b   Mulcahy, Fiona ^b   Hopkins, Susan ^c   Spiers, J Paul ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; LOPINAVIR; MESSENGER RNA; PEGINTERFERON ALPHA2A; RIBAVIRIN; SAQUINAVIR; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPRESSION; GENE; GENE EXPRESSION REGULATION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MACROPHAGE; MATRIX METALLOPROTEINASE 9 GENE; MIXED INFECTION; MONOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL; TOXICITY TESTING; ZYMOGRAPHY;

ADULT; ANTIVIRAL AGENTS; CELL LINE; COHORT STUDIES; COINFECTION; FEMALE; GREAT BRITAIN; HEPACIVIRUS; HEPATIC STELLATE CELLS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; IRELAND; LOPINAVIR; MALE; MONOCYTES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SAQUINAVIR; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VIRAL LOAD;

EID: 83455206882     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1867     Document Type: Article

References (45)

1. Yeni P. Update on HAART in HIV. J Hepatol 2006; 44:S100-S103. (Pubitemid 43053883)
2. Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol 2009; 15:3713-3724.
3. Mastroianni CM, Liuzzi GM. Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 2007; 13:449-459. (Pubitemid 350086978)
4. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta 2006; 364:33-60. (Pubitemid 43120627)
5. Khan F, Peltekian KM, Peterson TC. Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation. J Interferon Cytokine Res 2008; 28:643-651.
6. Friedman SL. Mac the knife? Macrophages- the double-edged sword of hepatic fibrosis. J Clin Invest 2005; 115:29-32. (Pubitemid 40385501)
7. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92:827-839. (Pubitemid 36542523)
8. Zhou X, Hovell CJ, Pawley S, et al. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver Int 2004; 24:492-501. (Pubitemid 40484564)
9. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol 2000; 113:443-453. (Pubitemid 30436163)
10. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35:297-306. (Pubitemid 32803489)
11. Cao Q, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine prevents transforming growth factor-beta1-mediated collagen accumulation in cultured rat hepatic stellate cells. J Lab Clin Med 2002; 139:202-210. (Pubitemid 34557355)
12. Roderfeld M, Weiskirchen R, Wagner S, et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J 2006; 20:444-454. (Pubitemid 44933321)
13. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115:56-65. (Pubitemid 40385505)
14. Díaz-Sanjuán T, Garcia-Ruiz I, Rodriguez-Juan C, Munoz-Yague T, Solis-Munoz P, Solis-Herruzo JA. Interferon alpha increases metalloproteinase-13 gene expression through a polyomavirus enhancer activator 3-dependent pathway in hepatic stellate cells. J Hepatol 2009; 50:128-139.
15. Liuzzi GM, Mastroianni CM, Latronico T, et al. Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 2004; 127:398-407. (Pubitemid 38160324)
16. Latronico T, Liuzzi GM, Riccio P, et al. Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. AIDS 2007; 21:677-684. (Pubitemid 46568624)
17. Liuzzi GM, Mastroianni CM, Santacroce MP, et al. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol 2000; 6:156-163. (Pubitemid 30303574)
18. Mellanen L, Salo T, Ingman T, Konttinen YT, Lahdevirta J, Sorsa T. 72-kDa and 92-kDa gelatinases in saliva of patients with human immunodeficiency virus infection. Acta Odontol Scand 1998; 56:135-142. (Pubitemid 128514044)
19. Sundstrom JB, Mosunjac M, Martinson DE, et al. Effects of norepinephrine, HIV type 1 infection, and leukocyte interactions with endothelial cells on the expression of matrix metalloproteinases. AIDS Res Hum Retroviruses 2001; 17:1605-1614. (Pubitemid 34072816)
20. Koulentaki M, Valatas V, Xidakis K, et al. Matrix metalloproteinases and their inhibitors in acute viral hepatitis. J Viral Hepat 2002; 9:189-193. (Pubitemid 36005516)
21. Lichtinghagen R, Bahr MJ, Wehmeier M, et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond) 2003; 105:373-382. (Pubitemid 37088577)
22. Mastroianni CM, Liuzzi GM, D'Ettorre G, et al. Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV. HIV Clin Trials 2002; 3:310-315. (Pubitemid 34830682)
23. Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother 2005; 49:3997-4008. (Pubitemid 41400938)
24. Dahari H, Affonso de Araujo ES, Haagmans BL, et al. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: Implications for treatment outcomes. J Hepatol 2010; 53:460-467.
25. von Hentig N, Babacan E, Lennemann T, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother 2008; 62:579-582.
26. Klein CE, Chiu YL, Cai Y, et al. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. J Clin Pharmacol 2008; 48:553-562. (Pubitemid 351503512)
27. Bittner B, Riek M, Holmes B, Grange S. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther 2005; 10:803-810. (Pubitemid 41652974)
28. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008; 47:351-371. (Pubitemid 351685386)
29. Marier JF, Manthos H, Kebir S, et al. Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. Int J Clin Pharmacol Ther 2006; 44:240-246. (Pubitemid 43676443)
30. Liu P, Foster G, LaBadie RR, Gutierrez MJ, Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008; 48:73-84. (Pubitemid 350292275)
31. Tarinas A, Tapanes RD, Gonzalez D, Ferrer G, Abreu D, Perez J. Bioequivalence study of two nevirapine tablet formulations in human-immunodeficiency-virus-infected patients. Farm Hosp 2007; 31:165-168. (Pubitemid 47373066)
32. Hopkins S, Lambourne J, Farrell G, et al. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. HIV Med 2006; 7:248-254.
33. Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995; 76:1197-1204.
34. Song G, Hennessy M, Zhao YL, et al. Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304). Pharmacol Res 2006; 54:57-64. (Pubitemid 44183712)
35. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101-1108. (Pubitemid 351818697)
36. Elkington PT, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005; 142:12-20. (Pubitemid 41361000)
37. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007; 46:955-975. (Pubitemid 46529049)
38. Bourlier V, Zakaroff-Girard A, De Barros S, et al. Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation. J Pharmacol Exp Ther 2005; 312:1272-1279. (Pubitemid 40293790)
39. Kuo WH, Chou FP, Lu SC, Chu SC, Hsieh YS. Significant differences in serum activities of matrix metalloproteinase-2 and -9 between HCV- and HBV-infected patients and carriers. Clin Chim Acta 2000; 294:157-168.
40. De Barros S, Zakaroff-Girard A, Lafontan M, Galitzky J, Bourlier V. Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9. J Pharmacol Exp Ther 2007; 320:291-299. (Pubitemid 46025743)
41. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47:124-129. (Pubitemid 36070352)
42. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38:481-492. (Pubitemid 36919870)
43. Mitsuda A, Suou T, Ikuta Y, Kawasaki H. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C. J Hepatol 2000; 32:666-672. (Pubitemid 30180388)
44. Pineda JA, Macias J, Mira JA, Merchante N, Del VJ, Neukam KI. HAART and the liver: friend or foe? Eur J Med Res 2010; 15:93-96.
45. Mariné-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18:2163-2170. (Pubitemid 39463681)